LB PHARMACEUTICALS INC
Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.
LBRX | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 575 MADISON AVENUE, 10022 NEW YORK
- Website:
- https://lbpharma.us/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for neuropsychiatric diseases. The company's pipeline is centered on its lead product candidate, LB-102, an oral small molecule aimed at treating schizophrenia, bipolar depression, and other central nervous system (CNS) disorders. LB Pharmaceuticals is focused on leveraging the therapeutic potential of LB-102, which it believes could become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all LB PHARMACEUTICALS INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for LB PHARMACEUTICALS INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for LB PHARMACEUTICALS INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
%20LTD/other/Cuprina_Holdings_Cayman_LTD-logo.png){kind=logo}
